Smith & Nephew plc (SNN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Smith & Nephew plc (SNN) trades at $33.34 with AI Score 50/100 (Hold). Smith & Nephew plc is a global medical technology company specializing in orthopedic reconstruction, sports medicine, and advanced wound management. Market cap: 14578162983, Sector: Healthcare.
Last analyzed: Feb 8, 2026Smith & Nephew plc (SNN) Healthcare & Pipeline Overview
Smith & Nephew (SNN) is a global leader in medical technology, offering innovative solutions in orthopedic reconstruction, sports medicine, and wound management, driven by a robust product portfolio, strategic acquisitions, and a commitment to improving patient outcomes, trading at a P/E of 30.48 with a 2.27% dividend yield.
Investment Thesis
Smith & Nephew presents a notable research candidate driven by its diversified product portfolio, global presence, and focus on innovation within the growing medical device market. The company's strong positions in orthopedic reconstruction, sports medicine, and advanced wound management provide multiple avenues for growth. With a gross margin of 70.0% and a profit margin of 8.3%, SNN demonstrates financial stability and efficiency. Upcoming product launches in sports medicine and wound care are expected to drive revenue growth in the next 1-2 years. The company's beta of 0.65 indicates lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. A dividend yield of 2.27% provides additional income, enhancing the overall investment appeal.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $15.17 billion reflects a strong market presence and investor confidence.
- Gross margin of 70.0% demonstrates efficient cost management and pricing power.
- Profit margin of 8.3% indicates healthy profitability within the competitive medical device industry.
- Dividend yield of 2.27% provides a steady income stream for investors.
- Beta of 0.65 suggests lower volatility compared to the overall market, offering stability.
Competitors & Peers
Strengths
- Diversified product portfolio across multiple medical device segments.
- Global presence and established distribution network.
- Strong brand reputation and relationships with healthcare providers.
- Commitment to innovation and research and development.
Weaknesses
- Exposure to regulatory risks and healthcare policy changes.
- Competition from larger medical device companies.
- Potential for product recalls and liability claims.
- Dependence on third-party suppliers for certain components.
Catalysts
- Launch of new sports medicine products in Q3 2026, expected to drive revenue growth in the sports medicine segment.
- Expansion in emerging markets, particularly in Asia and Latin America, is expected to contribute to long-term growth.
- Investment in research and development to drive innovation and new product development.
Risks
- Regulatory changes and healthcare policy reforms could impact reimbursement rates and market access.
- Product recalls and liability claims could result in financial losses and reputational damage.
- Intense competition from established medical device companies could limit market share gains.
- Economic downturns and healthcare spending cuts could reduce demand for medical devices.
Growth Opportunities
- Expansion in Emerging Markets: Smith & Nephew has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending and demand for advanced medical technologies. By establishing strategic partnerships and tailoring its product offerings to local needs, Smith & Nephew can capture a larger share of these markets. This expansion could contribute to a 10-15% increase in overall revenue within the next 3-5 years.
- New Product Development in Sports Medicine: The sports medicine market is driven by increasing participation in sports and a growing awareness of minimally invasive surgical techniques. Smith & Nephew can capitalize on this trend by investing in the development of innovative products for joint repair and soft tissue reconstruction. Launching new products in this segment could lead to a 8-12% increase in sports medicine revenue over the next 2-3 years.
- Advanced Wound Care Innovation: The market for advanced wound care is growing due to the rising prevalence of chronic diseases such as diabetes and obesity. Smith & Nephew can drive growth by developing advanced wound care products that promote faster healing and reduce the risk of infection. Focus on bioactives and regenerative medicine could lead to a 10-15% growth in the wound care segment within the next 3-4 years.
- Strategic Acquisitions: Smith & Nephew has a history of successful acquisitions that have expanded its product portfolio and geographic reach. The company can continue to pursue strategic acquisitions to strengthen its position in key markets and gain access to new technologies. Identifying and integrating complementary businesses could add 5-10% to overall revenue growth over the next 2-5 years.
- Digital Health Integration: Integrating digital health solutions into its product offerings can enhance patient outcomes and improve efficiency for healthcare providers. Smith & Nephew can develop digital platforms for remote patient monitoring, surgical planning, and post-operative care. This integration could lead to increased customer loyalty and a competitive advantage, contributing to a 5-8% increase in revenue within the next 3-5 years.
Opportunities
- Expansion in emerging markets with growing healthcare demand.
- Development of new products and technologies in sports medicine and wound care.
- Strategic acquisitions to expand product portfolio and market reach.
- Integration of digital health solutions to enhance patient outcomes.
Threats
- Intense competition from established medical device companies.
- Pricing pressures and reimbursement challenges.
- Economic downturns and healthcare spending cuts.
- Technological disruptions and changing customer preferences.
Competitive Advantages
- Strong brand reputation and established relationships with healthcare providers.
- Diversified product portfolio across multiple medical device segments.
- Global distribution network and market presence.
- Continuous innovation and investment in research and development.
About SNN
Smith & Nephew plc, established in 1856, has grown from a small family business to a global medical technology company. The company develops, manufactures, and markets a diverse portfolio of medical devices, focusing on orthopedic reconstruction, sports medicine, and advanced wound management. Its orthopedic reconstruction segment provides knee and hip implants designed for joint replacement procedures. The sports medicine division offers a range of products for minimally invasive surgery of the joints, including instruments, technologies, and implants for soft tissue repair. Smith & Nephew's advanced wound management solutions address acute and chronic wounds, offering products for wound healing, bioactives, and negative pressure wound therapy. Headquartered in Watford, United Kingdom, Smith & Nephew serves healthcare providers worldwide. The company's success is built on a foundation of innovation, strategic acquisitions, and a commitment to improving patient outcomes. With a market capitalization of $15.17 billion, Smith & Nephew maintains a strong presence in the global medical device market, competing with major players through its comprehensive product offerings and established distribution networks. The company's evolution reflects its ability to adapt to changing healthcare needs and technological advancements, solidifying its position as a trusted partner for healthcare professionals.
What They Do
- Develops and manufactures orthopedic reconstruction implants for knee and hip replacement.
- Offers sports medicine joint repair products for minimally invasive surgery.
- Provides advanced wound care products for acute and chronic wounds.
- Supplies arthroscopic enabling technologies for surgical visualization.
- Offers trauma and extremities products for fracture stabilization.
- Provides regenerative medicine products including skin, bone graft, and articular cartilage substitutes.
Business Model
- Develops and manufactures medical devices.
- Markets and sells products directly to healthcare providers.
- Generates revenue through product sales and related services.
- Invests in research and development to innovate new products.
Industry Context
Smith & Nephew operates in the global medical device industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand driven by an aging population and rising healthcare expenditures. The market for orthopedic reconstruction, sports medicine, and advanced wound management is expected to grow at a steady pace over the next decade. Competition is intense, with major players like Zimmer Biomet (CNC), Stryker (COO), and Fresenius Medical Care (FMS) vying for market share. Smith & Nephew differentiates itself through its diversified product portfolio, global reach, and focus on innovation.
Key Customers
- Hospitals and surgical centers.
- Orthopedic surgeons.
- Sports medicine specialists.
- Wound care clinics.
Financials
Chart & Info
Smith & Nephew plc (SNN) stock price: $33.34 (+0.46, +1.40%)
Latest News
-
How The S.N. Nuclearelectrica (BVB:SNN) Story Is Shifting As Fair Value Stays Put
Yahoo! Finance: SNN News · Mar 25, 2026
-
CONMED Taps Andrew Moller As Interim Finance Chief In Demand Slump
Yahoo! Finance: SNN News · Mar 24, 2026
-
How the FTSE grew comfortable with bumper pay for bosses
Yahoo! Finance: SNN News · Mar 21, 2026
-
European Equities Traded in US as ADRs Tumble in Tuesday Trading
MT Newswires · Mar 3, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNN.
Price Targets
Wall Street price target analysis for SNN.
MoonshotScore
What does this score mean?
The MoonshotScore rates SNN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
How The S.N. Nuclearelectrica (BVB:SNN) Story Is Shifting As Fair Value Stays Put
CONMED Taps Andrew Moller As Interim Finance Chief In Demand Slump
How the FTSE grew comfortable with bumper pay for bosses
European Equities Traded in US as ADRs Tumble in Tuesday Trading
Smith & Nephew plc ADR Information
Smith & Nephew plc (SNN) trades in the U.S. as an American Depositary Receipt (ADR).
What Investors Ask About Smith & Nephew plc (SNN) — Healthcare
What does Smith & Nephew plc do?
Smith & Nephew plc is a global medical technology company that develops, manufactures, and markets a wide range of medical devices. The company's core focus areas include orthopedic reconstruction, sports medicine, and advanced wound management. In orthopedics, they provide implants for knee and hip replacements. Their sports medicine division offers products for minimally invasive joint repair, while the advanced wound management segment focuses on solutions for acute and chronic wounds. Smith & Nephew serves healthcare providers worldwide, offering innovative solutions to improve patient outcomes.
Is SNN stock worth researching?
SNN stock presents a mixed outlook. The company's diversified product portfolio and global presence offer stability and growth potential. A P/E ratio of 30.48 indicates a premium valuation, reflecting investor expectations for future growth. The dividend yield of 2.27% provides an income component. Key growth drivers include expansion in emerging markets and new product launches. However, investors may want to evaluate the risks associated with regulatory changes and intense competition. A balanced approach, considering both growth prospects and potential risks, is essential when evaluating SNN as an investment.
What are the main risks for SNN?
Smith & Nephew faces several key risks. Regulatory changes in healthcare policies and reimbursement rates could negatively impact revenue. Intense competition from larger medical device companies poses a threat to market share. Product recalls and liability claims could result in significant financial losses. Economic downturns and healthcare spending cuts could reduce demand for medical devices. Additionally, technological disruptions and changing customer preferences could render existing products obsolete. These risks should be carefully considered when assessing the investment potential of Smith & Nephew.
What are the key factors to evaluate for SNN?
Smith & Nephew plc (SNN) currently holds an AI score of 50/100, indicating moderate score. Key strength: Diversified product portfolio across multiple medical device segments. Primary risk to monitor: Regulatory changes and healthcare policy reforms could impact reimbursement rates and market access. This is not financial advice.
How frequently does SNN data refresh on this page?
SNN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SNN's recent stock price performance?
Recent price movement in Smith & Nephew plc (SNN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across multiple medical device segments. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SNN overvalued or undervalued right now?
Determining whether Smith & Nephew plc (SNN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SNN?
Before investing in Smith & Nephew plc (SNN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.